Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
Clinically relevant 50 mg strength High-purity pharmaceutical-grade compound Backed by preclinical metabolic science Integrates well with NAD optimization and fat-loss regimens No known hormonal effects
General Storage Guidelines To ensure the longevity and integrity of your peptides, follow these general storage guidelines: Temperature: Store peptides at temperatures between 2C and 8C (36F and 46F)
The available evidence consists primarily of animal studies and limited early-phase human trials, with no published phase III clinical trial data demonstrating efficacy in inflammatory bowel disease (IBD).[1][2] The literature describes BPC-157 as a stable gastric pentadecapeptide that was tested in phase II clinical trials for inflammatory bowel disease (referenced as PL 14736), with reports indicating it was "safe" and had "no side effects." However, a 2025 review emphasizes that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans."[1][3][2] The preclinical evidence is extensive but limited to animal models
European Neurology, 27 (2), 120129.
Solvent selection should align with assay compatibility and stability considerations
Similarly the distance between the furcation and the resorbed interradicular bone surface was increased by the ligature, and this was partly reversed by BPC 157
US$ 29.56
US$ 22.56
US$ 20.94
US$ 21.82
US$ 28.30
US$ 25.23
US$ 27.65
US$ 23.64
US$ 28.73
US$ 23.51
US$ 29.81